ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Janeiro 2024 - 10:00AM
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a
clinical-stage immuno-oncology company developing therapies that
block the CD47 checkpoint pathway, announced today that Jason
Lettmann, Chief Executive Officer of ALX Oncology, will present a
company overview at the 42nd Annual J.P. Morgan Healthcare
Conference being held in San Francisco, CA on January 8th -11th,
2024. Mr. Lettmann’s presentation will take place on Monday,
January 8th at 4:30 PM PST.
A live webcast of the presentation is available (click link) and
can also be accessed by visiting the Investors section of ALX
Oncology’s website at www.alxoncology.com and
selecting Events under the News and Events tab. A replay
of the webcast will be archived for up to 30 days following the
presentation date.
About ALX Oncology
ALX Oncology is a publicly traded, clinical-stage
immuno-oncology company focused on helping patients fight cancer by
developing therapies that block the CD47 immune checkpoint
inhibitor and bridge the innate and adaptive immune system. ALX
Oncology’s lead product candidate, evorpacept, is a next generation
CD47 blocking therapeutic that combines a high-affinity CD47
binding domain with an inactivated, proprietary Fc domain.
Evorpacept has demonstrated promising clinical responses across a
range of hematologic and solid malignancies in combination with a
number of leading anti-cancer antibodies. ALX Oncology is currently
focusing on combining evorpacept with anti-cancer antibodies,
antibody-drug conjugates (“ADCs”), and PD-1/PD-L1 immune checkpoint
inhibitors.
Evorpacept’s Rational Design and Dual Development
Pillars
Rationally engineered with an inactive Fc effector function,
evorpacept’s clinical data to date has demonstrated a substantially
improved safety profile over other anti-CD47 molecules in the
clinic with an active Fc (i.e., binding the Fc gamma receptor on
macrophages). This superior safety profile allows higher dosing
with minimal overlapping toxicity in the combination treatment
setting. CD47 expressed on cancer cells binds to its receptor SIRP
alpha, which is predominantly expressed on two cell types:
macrophages and dendritic cells. ALX Oncology is focusing
evorpacept development with the standard-of-care agents as
originally designed revolving around these two cell types,
including:
Anti-cancer antibodies (the “don’t eat
me” signal): evorpacept enables Fc-mediated
antibody-dependent phagocytosis by macrophages in combination with
anti-cancer antibodies (e.g., Herceptin®) with an active Fc domain,
which is otherwise impaired by CD47 expression on cancer cells
binding to SIRP alpha on macrophages. This same mechanism of action
applies to ADCs.
PD-1/PD-L1 immune checkpoint inhibitors (the
“don’t activate T-cells” signal):
evorpacept enables T-cell activation by dendritic cells that are
constitutively inhibited by CD47 expression on cancer cells binding
to SIRP alpha on dendritic cells. Activated dendritic cells present
neoantigens to T-cells that once activated will kill cancer cells
when the PD-1/PD-L1 inhibitory interaction is blocked by T-cell
checkpoint inhibitors.
Investor Contacts:
Peter Garcia
Chief Financial Officer, ALX Oncology
(650) 466-7125 Ext. 113
peter@alxoncology.com
Malini Chatterjee, Ph.D.
Blueprint Life Science Group
mchatterjee@bplifescience.com
Media Contact:
Karen Sharma MacDougall
(781) 235-3060
alx@macdougall.bio
ALX Oncology (NASDAQ:ALXO)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
ALX Oncology (NASDAQ:ALXO)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024